View:
Download DOC
Download PDF
Download XLS
Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 6, 2008

Date of Report (Date of earliest event reported)

 

 

PRO-PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

NEVADA   000-32877   04-3562325

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

7 WELLS AVENUE

NEWTON, MASSACHUSETTS

02459

(Address of Principal Executive Offices) (Zip Code)

(617) 559-0033

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 7.01. Regulation FD Disclosure.

Theodore Zucconi, Ph.D., President of Pro-Pharmaceuticals, Inc. (“Company”), today is presenting a corporate update as reflected in the slides attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) at a Russ Trading Investor Meeting in Tempe, AZ, and is scheduled to present a corporate update at the Red Chip Small Cap Investor Conference tomorrow in Scottsdale, AZ.

The information in this Report, including the slides attached hereto as Exhibit 99.1, is being furnished pursuant to this Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

By filing this Report and furnishing this information, the Company makes no admission as to the materiality of any information in this Report. The information contained in the slides is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The Company cautions you that information included in the slides attached hereto as Exhibit 99.1 that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause the Company’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such forward-looking statements are made based on management’s current expectations and beliefs and should not be regarded as a statement or representation by the Company that any of its plans, including its anticipated milestones, will be achieved on time or at all. The Company’s public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company assumes no obligation to revise or update any forward-looking statement, including any information included in the slides attached hereto as Exhibit 99.1, to reflect events or circumstances arising after the date on which it was made. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

 

Item 8.01. Other Events.

On January 30, 2008, Custom Equity Research, Incorporated (d/b/a Summer Street Research Partners) (“Summer Street”) filed a lawsuit against the Company in the Superior Court of the Commonwealth of Massachusetts, alleging claims for breach of contract, declaratory judgment and unjust enrichment arising out of an engagement letter under which Summer Street agreed to provide institutional investment placement services to the Company. Summer Street claims it is entitled to a placement fee for each placement made during the term of the agreement and for each issuance of securities made or agreed to be made by the Company from October 17, 2007 through November 16, 2008. The Company believes the lawsuit is without merit and intends to contest it vigorously.

 

Item 9.01. Financial Statements and Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Index to Exhibits filed with this report.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

PRO-PHARMACEUTICALS, INC.
By:   /s/ Anthony Squeglia
 

Anthony Squeglia

Chief Financial Officer

Date: February 6, 2008

Exhibit Index

 

Number

Exhibit

   

Exhibit

99.1    Russ Trading Investor Meeting - Presentation Slides - dated February 6, 2008.
Russ Trading Investor Meeting - Presentation Slides
P  R  O      -
P  H  A  R  M  A  C  E  U  T  I  C  A  L  S ,    I  N  C .
Amex: P R W
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E®
Exhibit 99.1

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Forward Looking Statements
Any
statements
in
this
presentation
about
future
expectations,
plans
and
prospects
for
the
Company,
including
statements
containing
the
words
"believes,"
"anticipates,"
"plans,"
"expects
and
similar
expressions,
constitute
forward
looking
statements,
which
are
subject
to
the
safe
harbor
for
such
statements
in
the
Private
Securities
Litigation
Reform
Act
of
1995.
Future
events
could
cause
actual
results
to
differ
materially
from
those
indicated
by
such
statements.
Reference
is
made
to
the
factors
discussed
in
the
"Plan
of
Operations"
and
"Risk
Factors"
sections
of
the
Company's
most
recent
quarterly
or
annual
report
filed
with
the
Securities
and
Exchange
Commission.
The
forward-
looking
statements
herein
represent
the
Company's
views
as
of
the
date
of
this
presentation
and
should
not
be
relied
upon
to
represent
the
Company's
views
as
of
a
subsequent
date.
While
the
Company
anticipates
that
subsequent
events
may
cause
the
Company's
views
to
change,
the
Company
disclaims
any
obligation
to
update
such
forward-
looking statements.
2

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Mission
Develop proprietary carbohydrate
compounds with the potential to
significantly improve treatments for 
cancer, liver, inflammatory and microbial
diseases. This improvement is based on
identifying and exploiting the unique
biological specificity carbohydrates have
for disease receptors.
3

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Summary
•
Unique Technology
–
Multiple drug platforms
•
Positive pre-clinical and clinical trial
results
•
Regulatory Strategy
•
Business Opportunities
–
Multi-billion dollar markets
4

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Technology
5
•
Oncology
•
Fibrosis
•
Other opportunities

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Overview -
Technology
•
Unique Technology
–
Drug design using carbohydrates
–
Five
patents
issued
and
eleven
pending
–
Highly specific recognition mechanisms
6

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Strong Intellectual Property Position 
Carbohydrate Polymers
•
Composition of matter and field of use
patents (5)
–
U.S. Pat 6,642,205
(11/04/03) –
Methods and
Compositions for Reducing side effects in
Chemotherapeutic Treatments
–
U.S. Pat 6,645,946
(11/11/03) & U.S. Pat 6,982,255
(01/03/06) & U.S. Pat 6,914,055
(07/05/06) –
Delivery of
a Therapeutic Agent in a Formulation for Reduced
Toxicity
–
U.S. Pat 7,012,068
(03/14/06) –
Co-administration of a
Polysaccharide with a Chemotherapeutic agent for the
Treatment of Cancer
7

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Composition of Matter and Methods of Delivery
Key Claims
•
Methods and compositions for reducing toxicity of an
existing chemotherapeutic drug by co-administering a
polysaccharide
•
UNIVERSAL CARBOHYDRATE LINKER
TECHNOLOGY (UCLT™) enhances the delivery of
chemotherapy drugs to tumor cells
•
Covalently binds one carbohydrate compound to a
chemotherapy drug
•
Utilizes carbohydrate specific receptors found on
cancer cells to target delivery
8

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Strong Intellectual Property Position 
11 new patent applications filed
•
2 -
enhanced treatment of cancer
including reduced side effects
•
3 -
delivery of anti-cancer drugs
•
1 -
reducing side effects of
chemotherapeutic treatments
•
1 -
formulation for anti-fibrotic therapies
•
2 –
carbohydrate derived statins
•
1 -
composition of anti-microbial agent
•
1-
compositions and methods to inhibit
restenosis
9

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
LEAD COMPOUND
10

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Targeting Lectins
•
Lectins are proteins that tightly bind certain
carbohydrates
•
Galectins are a type of lectin that specifically bind
galactose molecules
•
Galectin receptors are predominately on cancer
cells
•
Galectins have been shown to affect cell
development, differentiation, apoptosis and tumor
metastasis
11

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
•
Proprietary polysaccharide that targets
Galectin receptors on cancer cells
•
Increases efficacy and decreases toxicity of
chemotherapeutic agents
•
Currently in Phase ll trials
DAVANAT
®
12

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
•
DAVANAT
®
selectively binds to lectin
receptors on cancer cells
•
Once bound, the polymer releases its
payload into the cancer cell
Oncology Platform: CARBOSOME™
13

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Second
Platform:
Universal Carbohydrate Linker Technology
•
New chemical entity that contains a carbohydrate backbone
14

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
CLINICAL TRIAL RESULTS
15

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Pre-Clinical Results
DAVANAT®
mixed with Avastin®
and with 5-FU
showed best results –
SLOWEST TUMOR GROWTH
Tumor Weight Gain in Mice Implanted with COLO 205, Human
Colon Tumor, Treated with DAVANAT® in Combination with 5-FU
& Bevacizumab (Avastin®)
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU  50 mg/kg; DAVANAT®:  120 mg/kg;
AVASTIN:  20-80 mg/kg)
No Treatment
AV
FU / AV
FU-DAV / AV
FU-DAV / AV-DAV
16

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Pre-Clinical Results
DAVANAT®
mixed with Avastin and with 5-FU showed
best results –
Mice Show Healthy Weight Gain
Total Weight Gain of Mice Implanted with COLO 205, Human Colon
Tumor, Treated with DAVANAT® in Combination with 5-FU &
Bevacizumab (Avastin®)
-8.0
-4.0
0.0
4.0
8.0
Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU  50 mg/kg; DAVANAT®:  120 mg/kg; AVASTIN:
20-80 mg/kg)
No Treatment
AV
FU / AV
FU-DAV / AV
FU-DAV / AV-DAV
17

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Pre-Clinical Results
DAVANAT®
mixed with Avastin and with 5-FU showed best   
results –
Clinical Benefit Index = Lowest Toxicity and Best Efficacy
18

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
0
10
20
30
40
0
10
20
30
40
AUC
Hematocrit
Hemoglobin
Red blood cells
White blood cells
Platelets
Clinical  Trial Results
DAVANAT®
mixed with 5-FU eliminated the
expected drop in blood levels from chemotherapy
19

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Clinical Trial Summary
Results
•
48
patients
dosed
with
DAVANAT
®
/5-FU
in
Phase
l/ll,
Line
three
and
four
clinical
trials
•
Stabilized
43%
of
end
stage
patients
with
measurable
disease:       
2-13 months
•
Maximum
Tolerated
Dose/Dose
Limiting
Toxicity
not
reached
•
DAVANAT
®
allowed
increased
5-FU
exposure
with
no
toxicity
increase
Ongoing
•
Dosing
biliary
and
colorectal
cancer
patients
in
Phase
ll,
line
one
trials:
–
Colorectal
(8
patients
dosed)
–
3
PR;
4
stabilized
up
to
10
months
–
43%
Objective
Response
(more
than
30%
shrinkage)
20

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Beyond Oncology
-New Platforms-
•
Use Proprietary IP to Design New Drugs
•
Fibrosis –
Multiple Indications
•
Anti-Microbial
•
Synthetic Statins (Cholesterol)
21

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
FIBROSIS
22

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Fibrosis -
Background
•
Worldwide, 170 million people are infected with chronic hepatitis C
•
10-40% of patients respond to current therapies (notably, removal 
of cause)
–
There are no effective therapeutic options
–
1.4 million deaths per year attributed to chronic liver disease
–
In the U.S., liver disease is a top 10 disease-related cause of
death
•
Liver fibrosis is an outcome of persistent hepatic inflammation
•
World wide market in excess of $4 billion
•
Research collaboration with Dr. Scott Friedman, Director Liver
Diseases, Mt. Sinai School of Medicine & President, American
Association for the Study of Liver Diseases
•
PRO-GR
300,
a
first
in
class,
carbohydrate
compound
has
shown
in
pre-clinical
models
to
not
only
arrest
disease
progression
but
also
to
reverse
disease
progression
23

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Reduces
the
production
of
Collagen
Collagen
is
central
to
fibrogenesis
diseases
and
the
scarring
of
organs.
Reduces Expression of Matrix
Metalloproteinase -2 (MMP-2)
MMP-2 has been correlated to the
severity
of
fibrosis
in
hepatitis
C.
Reduces Expression of TGFBR1
TGFBR1 plays a key role in initiating the
cascade of events  causes the formation
of
fibrosis
/
scar
tissue
Mechanism of Action -
Mechanism of Action -
Effect
Effect
on Fibrotic Markers In-vitro
on Fibrotic Markers In-vitro
Addition of PRO-GR 300 to fibrotic liver cells:
24

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Reversal of Fibrosis with
PRO–GR 300 after 4 weeks
of treatment
Liver Fibrosis, induced by injection
of chemical toxin for 8 weeks
Rat
Fibrosis
Model
Proof of Concept
Proof of Concept
25

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Other Fibrosis Applications
•
The same receptors influence many types of Fibrosis
•
Therefore PRO-GR 300 may be effective in different types of
Fibrosis
•
Chemical toxicity, microbial infection & physical injury cause
hepatic, renal, cardiac and pulmonary fibrosis
•
Kidney Fibrosis
–
12 million people suffer from kidney fibrosis in the U.S.
–
Research collaboration with Brigham and Women's
Hospital -
affiliate of Harvard Medical School
26

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Regulatory Strategy
27

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Regulatory Strategy
•
Submit final report for completed Phase II end stage patient trial
•
Continue Phase II trials underway
•
Drug Master File (Mfg data) to FDA
•
Initiate IND for non-intravenous indications, e.g., Melanoma
•
File for Approval to Market DAVANAT®
as Excipient with 5-FU
•
Animal studies needed to add DAVANAT®
to other chemos
•
Regional partnership approach for DAVANAT®
•
Partner for Phase III trials
Oncology
Fibrosis
•
Animal studies needed to extend proof of concept
•
Accelerate liver & kidney pre-clinical trials
•
File IND for human trials
•
Seek partnership
28

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Product Development Pipeline Jan 2008
PRODUCT
INDICATION
DISCOVERY
PRE-CLINICAL
PHASE 1
PHASE 2
DAVANAT
®
/ 5-FU line I
DAVANAT
®
/ 5-FU/LV/
AVASTIN
®
line I
DAVANAT
®
/ 5-FU line IV
PRO-GR 300
Biliary Cancer
Ongoing
Colorectal  Cancer
Ongoing
All Solid Tumors
Completed
Liver Disease
Microbial Disease
PHASE 3
DAVANAT
®
/ 5-FU line IV
Colorectal Cancer
Completed
PRO-NAC 050
29

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
2008 Milestones
•
Submit Drug Master File (DMF) -
First Quarter
•
File Investigative New Drug (IND) Application: Triggers
FDA Review of DMF -
Second Quarter
•
DMF approval projected –
Second/Third Quarter
•
License DAVANAT®
in regions outside U.S. –
Third Quarter
•
Submit data needed for approval as excipient to 5-FU –
Fourth Quarter
•
Continue to complete research agreements
•
Actively pursue corporate partnerships
30

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Business Opportunities 
Several
Multi-billion dollar markets can
be addressed
31

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Business Opportunities
•
Oncology
–
Excipient to 5-FU, improve results & reduce side effects
–
Eliminates/reduces need for additional drugs to treat side effects
–
Extend patent life of chemo drugs
–
Only animal studies needed to combine with other chemo
–
New indications -
melanoma
–
Regional licenses
–
Partner with big Pharma to fund trials
•
Avastin®
sales in 2007 $2.9 billion –
Works with 5-FU
–
Low Cost to Produce
32

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Business Opportunities           
Several Multi-billion dollar markets can be
addressed
•
Fibrosis
–
Accelerate pre-clinical trials based on proven safety of
carbohydrates and DAVANAT®
•
Liver
•
Kidney
–
File IND
–
Start clinical trials ASAP
–
Early partnerships
–
New indications –
lung fibrosis
33

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
CORPORATE
34

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Corporate Summary
•
PRW began operations in 2001
•
Five U.S. patents issued
•
Capital raised: $39.5 million (cumulative)
•
Shares outstanding: 40.4 million (11/01/07)
•
Fully diluted: 52.1 million (11/01/07)
•
Completed Phase l/ll cancer trials, line 3-4
•
Two ongoing Phase ll trials, line 1, biliary & colorectal cancer
•
PRO-GR 300
in pre-clinical trials to treat fibrosis
•
Plan to commercialize technology and products through
corporate partnerships
•
Carbohydrate technology platform enables:
–
New intellectual property
–
Product line extensions
–
Safer and more effective drugs
35

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Management Team
•
David Platt, Ph.D., Chairman & Chief Executive Officer
–
Co-founder, co-developer of Glycoscience technology. Founder: SafeScience; developed
anti-angiogenesis drug.  U of Michigan, Weizmann Institute, Hebrew U
•
Theodore Zucconi, Ph.D., President
–
35 + years experience in operations management, R&D, problem solving, product
development and strategic planning
•
Anatole Klyosov, Ph.D., D.Sc., Chief Scientist
–
Co-founder, co-developer of Glycoscience technology. National Prize in Science &
Technology (Russia); Visiting Biochemistry Prof at Harvard.  Moscow State U
•
Eliezer Zomer, Ph.D., Exec. V.P., Clinical Development & Mfg
–
Former Research Associate at Harvard Medical
•
David Donabedian, Ph.D., MBA, Business Development (Consultant)
–
12 years in life sciences;  VP, Bus Dev, Surface Logix; Accenture;  Dow Chemical
•
Anthony Squeglia, MBA, Chief Financial Officer
–
25 years in finance, strategic planning, marketing & investor relations
•
Maureen Foley, Chief Operating Officer
–
25 years in biotech, high-tech in operations management
•
Bruce Silver, M.D., Medical Director (Consultant)
–
20 + years in oncology; CRO
36

P R O  
-
P H A R M A C E U T I C A L S ,  I N C.
A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E
®
Amex: P R W
Summary
•
Proprietary Technology With Multiple Current and
Future Applications
•
Excipient
for Existing Chemotherapy Protocols
•
Reduces or Eliminates Adverse Side Effects and
Lowers Cost of Treatment
•
Proven Effective in Targeting Lectin Receptors
Specific to Cancer Cells
•
New Compound (drug) has Shown Ability to
Reverse Liver Fibrosis
•
Oncology and Fibrosis –
Multi Billion Dollar Markets
37